Asset Details
Do you wish to reserve the book?
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
Do you wish to request the book?
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
2017
Overview
This proof-of-principle trial showed that imatinib treatment reduced mast-cell activation and improved airway responsiveness in patients with severe refractory asthma.
Many patients with severe asthma do not have adequate disease control despite the use of high-dose inhaled or systemic glucocorticoids.
1
Severe asthma is associated with airway hyperresponsiveness — that is, an exaggerated response to a bronchoconstrictor stimulus — and airway inflammation, both of which persist despite high-dose glucocorticoid therapy.
2
,
3
Increased airway hyperresponsiveness is associated with a progressive loss of lung function,
4
and, among patients with moderate-to-severe asthma, those with airway hyperresponsiveness have a poorer quality of life than those without this trait.
5
In addition, studies have shown that treatment targeting airway hyperresponsiveness leads to more effective control of asthma . . .
Publisher
Massachusetts Medical Society
Subject
/ Asthma
/ Bronchial Hyperreactivity - drug therapy
/ Female
/ Forced Expiratory Volume - drug effects
/ Humans
/ Imatinib Mesylate - adverse effects
/ Imatinib Mesylate - therapeutic use
/ Kinases
/ Male
/ Patients
/ Protein Kinase Inhibitors - adverse effects
